Laboratório de Citogenética, Centro de Estudos Avançados da Biodiversidade, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil; Universidade Federal Rural da Amazônia, Campus Tomé Açu, Tomé Açu, PA, Brazil.
Laboraratório de Imunohistoquímica e Biologia do Desenvolvimento, Instituto de Ciências Biológicas, Universidade Federal do Pará, Brazil.
Biomed Pharmacother. 2021 Jun;138:111505. doi: 10.1016/j.biopha.2021.111505. Epub 2021 Mar 24.
Doxorubicin (DOX) is an anthracycline antibiotic used in the fight against many types of cancer. Although it is quite effective for this purpose, its clinical use is limited by its severe side effects, highlighting the relevance of efforts to identify substances that act to minimize these effects. In this work, we sought to verify the ability of andiroba oil (AO) and a nanoemulsion of andiroba oil (AN) to lessen the side effects of DOX. The animals were separated into 7 groups with 6 animals each: mice treated with AO (2000 mg/kg), AN (2000 mg/kg), the antineoplastic agent DOX (40 mg/kg), AO+DOX, AN+DOX and solvent controls was used of negative control (corn oil and nanoemulsion surfactant). AO and AN were administered for 14 consecutive days orally by gavage and on the 13th day, applied DOX by intraperitoneal route (i.p.), in order to evaluate the protective potential of andiroba. The animals were euthanized on the 15th day. Hematological, biochemical, histological, and immunohistochemical parameters were analyzed. Andiroba reduced several aspects of the severity of lesions caused by DOX, decreasing hematotoxicity and the severity of histological changes in the liver and kidneys, and reducing the frequency of apoptotic cell death. In many cases, AN showed greater efficacy than AO alone, reflecting the feasibility of using this nanotechnology to improve the pharmacokinetics of lipid compounds in the body. The study sheds new light on the therapeutic benefits of andiroba and suggests new ways for investigating how the quantity and quality of lipid compounds affect exposed organisms.
多柔比星（DOX）是一种用于治疗多种癌症的蒽环类抗生素。尽管它在这方面非常有效，但由于其严重的副作用，其临床应用受到限制，这突显了努力寻找能够减轻这些副作用的物质的重要性。在这项工作中，我们试图验证巴西棕榈油（AO）和巴西棕榈油纳米乳液（AN）减轻 DOX 副作用的能力。将动物分为 7 组，每组 6 只：用 AO（2000mg/kg）、AN（2000mg/kg）、抗肿瘤药物 DOX（40mg/kg）、AO+DOX、AN+DOX 和溶剂对照（玉米油和纳米乳液表面活性剂）处理的小鼠。AO 和 AN 通过灌胃连续 14 天给药，第 13 天经腹腔（i.p.）给予 DOX，以评估巴西棕榈的保护潜力。第 15 天处死动物。分析血液学、生化、组织学和免疫组织化学参数。巴西棕榈降低了 DOX 引起的损伤严重程度的几个方面，降低了血液毒性和肝肾功能组织学变化的严重程度，并降低了细胞凋亡的频率。在许多情况下，AN 比单独使用 AO 更有效，这反映了使用这种纳米技术来改善体内脂质化合物药代动力学的可行性。该研究为巴西棕榈的治疗益处提供了新的视角，并为研究脂质化合物的数量和质量如何影响暴露的生物体提供了新的思路。
